Followers | 62 |
Posts | 24529 |
Boards Moderated | 0 |
Alias Born | 11/23/2016 |
Thursday, May 03, 2018 1:11:59 AM
How can this happen in a well designed and controlled BP trial costing more than the market cap of Anavex?
How did they convince themselves, their investors and not least their trial participants, not to mention the FDA, of promising P2 data?
https://www.alzforum.org/news/research-news/paper-alert-verubecestat-epoch-findings-published
“Paper Alert: Verubecestat EPOCH Findings Published
Quick Links
02 May 2018
Today Merck formally published the findings from the discontinued Phase 3 EPOCH trial of the BACE inhibitor verubecestat in mild to moderate Alzheimer’s disease. Michael Egan from Merck previously reported the bulk of the data at last year’s Clinical Trials on Alzheimer’s Disease conference (Dec 2017 conference news). The paper confirms that participants taking the drug declined at the same rate as the placebo group on the primary outcome measures, the ADCS-ADL and the ADAS-Cog11, as well as on a secondary measure, the CDR sum of boxes. The new analysis includes additional secondary measures, the MMSE and NPI, which also showed no difference between treatment and placebo groups. ApoE4 carriers did not differ from noncarriers on any clinical measure.
The biomarker data did show some differences on drug. As reported previously, the treatment group had a slight decline in plaque load as measured by amyloid PET, with the SUVR falling by 0.02 to 0.04. They also lost slightly more hippocampal volume and total brain volume than controls. The paper adds data on cerebrospinal tau levels, reporting no difference between drug and placebo in either total tau or phosphorylated tau. As expected from the drug’s mechanism of action, levels of Aß40, Aß42, and sAPPß in CSF fell sharply, by up to 80 percent in the high-dose group.
Adverse events were more frequent in the treatment groups, with 9 percent of the high-dose group and 8 percent of the low-dose group stopping treatment because of them, compared with 6 percent of the placebo group. The most common side effects ascribed to the drug were rashes, falls, and insomnia. Rashes were almost twice as common in the treatment groups than in controls, with 10–12 percent of the former reporting them. Hair color changed in about 2 percent of people taking the BACE inhibitor, matching findings from animal studies. People in the treatment groups lost an average of 3.5 pounds during the trial.
Some psychiatric side effects cropped up, as well. The treatment groups had anxiety, while about 6 percent of participants on drug reported feeling suicidal, compared with 3 percent of controls. The investigators judged the severity of suicidal thoughts to be mild, and the majority of participants reporting them had a past history of psychiatric disorders. The researchers did not see any increase in delirium, nor any brain edema, with verubecestat treatment.—Madolyn Bowman”
Recent AVXL News
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • Oct 15, 2024 8:21 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
CBD Life Sciences, Inc. Announces Strategic MOU with U.S. Armed Forces for Groundbreaking Mushroom Supplement • CBDL • Oct 15, 2024 8:00 AM
HealthLynked Files Non-Provisional Patent for AI-Powered Healthcare Assistant, ARi • HLYK • Oct 15, 2024 8:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM